- primarily used in neonates for the treatment of Chlamydial infections (conjunctivitis, pneumonia)
- erythromycin ophthalmic ointment is used for prophylaxis of neonatal gonococcal or chlamydial conjunctivitis
- erythromycin is a macrolide antibiotic which binds to 50 S ribosomal subunits, thereby inhibiting protein synthesis in susceptible organisms
- erythromycin is active against Gram-positive cocci (staphylococci and streptococci) and Gram-positive bacilli (incl. Listeria monocytogenes) as well as some Gram-negative bacilli (incl. Legionella pneumophila)
- erythromycin is also active against some strains of Chlamydia and Mycoplasma pneumonia
- erythromycin is partly metabolized in the liver; it is mostly excreted unchanged in the bile
- GI (vomiting, diarrhea, abdominal pain)
- hypersensitivity (rash, fever, eosinophilia)
- local reactions (pain, venous irritation, phlebitis) when given by IV route
- give by slow IV infusion over 30 minutes, or orally
|< 7 days -
||10 mg/kg q12h
|> 7 days -
||10 mg/kg q8h
- for Chlamydial conjunctivitis or pneumonia, therapy should be continued for at least 14 DAYS
- topical therapy alone for conjunctivitis is NOT adequate, and is of no added benefit to systemic erythromycin
- for prophylaxis of neonatal gonococcal or chlamydial conjunctivitis a ribbon of ointment, 0.5 to 1 cm in length, should be instilled into each conjunctival sac
- available as the lactobionate salt
- 5 mg/mL syringe for IV use, prepared by the Pharmacy Department
TO PREPARE 5mg/mL STRENGTH
- 500 mg vial; add 20 mL of sterile water for injection to produce a concentration of 25 mg/mL; add 2 mL of 25 mg/mL to 8 mL sterile water for injection to produce a final concentration of 5 mg/mL
- Please Note: 5 mg/mL is the MAXIMUM recommended concentration
- erythromycin estolate, 50 mg/mL, suspension
- McEvoy G K (ed): AHFS Drug Information, American Society of Hospital Pharmacists, 1991.
- Cloherty JP and Stark AR (eds): Manual of Neonatal Intensive Care, Little, Brown and Company, 1991.
- Nelson JD: Pocketbook of Pediatric Antimicrobial Therapy, 7th Edition, 1987, Williams and Wilkins, Baltimore.
- Health and Welfare Canada: 1988 Canadian guidelines for the treatment of sexually transmitted diseases in neonates, children, adolescents and adults, Canada Diseases Weekly Report, 1988 (Apr); 14S2 (supplement): 6.
- Anon: Morbidity and Mortality Weekly Report, 1985; 34 (No.4S): 77S-79S.
- Roberts, RJ: Drug Therapy in Infants, W.B. Saunders, Toronto, 1984.
- Krogh CME et al (ed): Compendium of Pharmaceuticals and Specialties, Canadian Pharmaceutical Association, 1992.
- Bhatt DR, Furman GI, Reber DJ et al: Neonatal Drug Formulary, 1990-1991, 2nd Edition, Fontana, California 92334.
- Taketomo CK, Hodding JH and Kraus DM: Pediatric Dosage Handbook, Lexi-Comp Inc., Cleveland, 1992.